LQDA Stock Analysis
LQ
Uncovered
Liquidia Corp is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. The company is headquartered in Morrisville, North Carolina. The company went IPO on 2018-07-26. The firm operates, through its wholly owned subsidiaries, Liquidia Technologies and Liquidia PAH. Liquidia Technologies has developed YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic treprostinil injection. Its United Therapeutics developed treprostinil under the brand name Remodulin. The Company’s PRINT engineering technology allows to engineer and manufacture uniform drug particles with control over the size, three-dimensional geometric shape and chemical composition of the particles. The firm operates from over 45,000 square foot facility in Morrisville, North Carolina.